The 2015 Keystone Symposia Meeting - Pathways of Neurodevelopmental Disorders

  

Symposium - Tahoe City, CA, United States

 

 

Advances in genetics and animal models for many neurodevelopmental disorders have led to the development of targeted treatments that can reverse neurobiological abnormalities in the animal models. Human studies have begun to show significant benefit from targeted treatments for several neurodevelopmental disorders including fragile X syndrome, tuberous sclerosis, Angelman Syndrome, Down Syndrome, Rett Syndrome and neurofibromatosis with the potential for many more. There are remarkable commonalities in the dysfunction of key pathways and the molecular mechanisms involved in synaptic plasticity across neurodevelopmental disorders. This Keystone Symposia meeting covers advances in targeted treatments for several neurodevelopmental disorders with an emphasis on common pathways across disorders and treatments that may help more than one disorder. This conference also addresses the gap between how environmental factors including seizures and toxins can impact genetically vulnerable populations such as those with neurodevelopmental problems and the molecular mechanisms including mitochondrial dysfunction, oxidative stress, miRNA dysregulation and neuroinflammation that are involved. The goal of this conference is to stimulate development new treatments and biomarkers to assess treatments in neurodevelopmental disorders and to promote early intervention with prophylactic and targeted treatments. By pulling together basic science and translational clinical trials, and mixing clinicians with molecular and neurobiologists, the meeting should foster new ideas for treatment that will be beneficial across the spectrum of neurodevelopmental disorders.

Organization: Keystone Symposia

 

 

 

If you'd like to ask a question or post a comment about this talk please do so below.